Kura Oncology (KURA) COO sells 2,257 shares under pre-set trading plan

Rhea-AI Filing Summary

Kura Oncology, Inc. Chief Operating Officer Kathleen Ford reported an open-market sale of 2,257 shares of common stock on May 19, 2026 at a weighted average price of $9.0752 per share. The sale was executed under a pre-arranged Rule 10b5-1 trading plan adopted on August 29, 2025.

According to the filing, the 2,257 shares sold match 2,257 shares acquired on May 17, 2026 through the company’s Employee Stock Purchase Plan. After this transaction, Ford directly holds 153,560 shares of Kura Oncology common stock.

Insider Trade Summary 10b5-1

Net Seller: 2,257 shares ($20,483)

Net Sell 1 txn

Insider FORD KATHLEEN

Role Chief Operating Officer

Sold 2,257 shs ($20K)

Type	Security	Shares	Price	Value
Sale	Common Stock	2,257	$9.0752	$20K

Holdings After Transaction: Common Stock — 153,560 shares (Direct, null)

Footnotes (1)

1. The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 29, 2025. 2,257 shares were acquired on May 17, 2026 pursuant to the Issuer's Employee Stock Purchase Plan. This transaction was executed in multiple trades at prices ranging from $8.97 to $9.17. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

Key Figures

Shares sold: 2,257 shares Weighted average sale price: $9.0752 per share Approximate sale value: $20,500 +3 more

6 metrics

Shares sold 2,257 shares Open-market sale on May 19, 2026

Weighted average sale price $9.0752 per share Common stock sale on May 19, 2026

Approximate sale value $20,500 2,257 shares sold at ~$9.08 per share

Shares held after transaction 153,560 shares Direct holdings after May 19, 2026 sale

Net shares sold 2,257 shares Net-sell direction in transaction summary

Shares acquired via ESPP 2,257 shares Acquired on May 17, 2026 under Employee Stock Purchase Plan

Key Terms

Rule 10b5-1 trading plan, Employee Stock Purchase Plan, weighted average sale price, open-market sale

4 terms

Rule 10b5-1 trading plan regulatory

"The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted..."

A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.

Employee Stock Purchase Plan financial

"2,257 shares were acquired on May 17, 2026 pursuant to the Issuer's Employee Stock Purchase Plan."

An employee stock purchase plan is a company program that lets workers buy shares through small payroll deductions, often at a discount to the market price and after a set offering period. Think of it like a workplace savings plan that turns into ownership: it encourages employees to share in the company’s success and can create predictable buying or selling of stock that investors watch because it affects supply, demand and employee incentives.

weighted average sale price financial

"The price reported above reflects the weighted average sale price."

open-market sale financial

"transaction_action": "open-market sale""

An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

FORD KATHLEEN

(Last) (First) (Middle)

C/O KURA ONCOLOGY, INC.

4930 DIRECTORS PLACE, SUITE 500

(Street)

SAN DIEGO CALIFORNIA 92121

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Kura Oncology, Inc. [ KURA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Operating Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/19/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	05/19/2026		S(1)		2,257(2)	D	$9.0752(3)	153,560	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 29, 2025.

2. 2,257 shares were acquired on May 17, 2026 pursuant to the Issuer's Employee Stock Purchase Plan.

3. This transaction was executed in multiple trades at prices ranging from $8.97 to $9.17. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

	Teresa Bair, Attorney-in-fact for Kathleen Ford	05/20/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transaction did Kura Oncology (KURA) report for Kathleen Ford?

Kura Oncology reported that Chief Operating Officer Kathleen Ford sold 2,257 shares of common stock in an open-market transaction at a weighted average price of $9.0752 per share, executed under a pre-arranged Rule 10b5-1 trading plan.

At what price did the Kura Oncology COO sell shares reported on this Form 4?

The filing shows a weighted average sale price of $9.0752 per share for the 2,257 Kura Oncology shares sold, with individual trades executed between $8.97 and $9.17, as disclosed in the transaction’s detailed price range footnote.

How many Kura Oncology shares does Kathleen Ford hold after this reported sale?

Following the reported transaction, Chief Operating Officer Kathleen Ford directly holds 153,560 shares of Kura Oncology common stock, according to the Form 4, indicating she retains a substantial ongoing equity position in the company after the sale.

Was the Kura Oncology insider sale made under a Rule 10b5-1 trading plan?

Yes. The Form 4 discloses that the 2,257-share sale by Kura Oncology’s Chief Operating Officer was effected pursuant to a Rule 10b5-1 trading plan that she adopted on August 29, 2025, indicating the trade was pre-arranged rather than opportunistic.

How are the sold shares related to Kura Oncology’s Employee Stock Purchase Plan?

A Form 4 footnote states that the 2,257 shares sold were acquired two days earlier, on May 17, 2026, through Kura Oncology’s Employee Stock Purchase Plan, linking the sale directly to recent ESPP-related share acquisition activity.